Stockreport

Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF Ultragenyx discontinuing development of UX007 in Glut1 DS indication Company on track with separate UX007 program in LC-FAOD with pre-NDA meeting later this year NOVAT [Read more]